Kura Oncology, Inc. (KURA)
| Market Cap | 913.85M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -135.47M |
| Shares Out | 68.30M |
| EPS (ttm) | -2.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 549,105 |
| Open | 13.53 |
| Previous Close | 13.72 |
| Day's Range | 13.26 - 13.77 |
| 52-Week Range | 10.41 - 19.93 |
| Beta | 0.83 |
| Analysts | Buy |
| Price Target | 32.87 (+145.67%) |
| Earnings Date | Feb 23, 2023 |
About KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable i... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for KURA stock is "Buy." The 12-month stock price forecast is $32.87, which is an increase of 145.67% from the latest price.
News
Kura Oncology Announces FDA Clearance of IND Application for KO-2806, a Next-Generation Farnesyl Transferase Inhibitor
SAN DIEGO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...
Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at American Society of Hematology Annual Meeting
– 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML –– Low frequency of differentiation syndrome, including 5% rate (1/20) of ≥ Grade 3 among NPM1-mutant patients treated a...
Wall Street Analysts Believe Kura Oncology (KURA) Could Rally 111%: Here's is How to Trade
The consensus price target hints at an 110.5% upside potential for Kura Oncology (KURA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings e...
Kura Oncology to Host Investor Event on December 10, 2022
In-person event and live webcast to follow oral presentation of data from KOMET-001 at ASH in New Orleans In-person event and live webcast to follow oral presentation of data from KOMET-001 at ASH in ...
Is Kura Oncology (KURA) Stock Outpacing Its Medical Peers This Year?
Here is how Kura Oncology (KURA) and UnitedHealth Group (UNH) have performed compared to their sector so far this year.
Kura Oncology to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...
Wall Street Analysts Think Kura Oncology (KURA) Could Surge 116%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 115.6% in Kura Oncology (KURA). While the effectiveness of this highly sought-after metric is questionable, the...
Is Kura Oncology (KURA) Outperforming Other Medical Stocks This Year?
Here is how Kura Oncology (KURA) and Neurocrine Biosciences (NBIX) have performed compared to their sector so far this year.
Kura Oncology Announces Four Abstracts Accepted for Presentation at ASH Annual Meeting
Abstract featuring updated data from KOMET-001 trial of ziftomenib accepted for oral presentation on December 10, 2022 Abstract featuring updated data from KOMET-001 trial of ziftomenib accepted for o...
Kura Oncology Reports Third Quarter 2022 Financial Results
– Abstract reporting updated data from KOMET-001 accepted for oral presentation at ASH –
Kura Oncology to Report Third Quarter 2022 Financial Results
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...
Kura Oncology Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma
– First demonstration that precision combination therapies can achieve a durable clinical response in PIK3CA-dependent HNSCC –
Kura Oncology to Participate in H.C. Wainwright Global Investment Conference
SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Reports Second Quarter 2022 Financial Results
– Recommended Phase 2 dose for ziftomenib identified, pending FDA review –
Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference
SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...
Kura Oncology to Report Second Quarter 2022 Financial Results
SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...
Read Why Did Credit Suisse Raise Price Target On Kura Oncology
Credit Suisse has raised the price target on Kura Oncology Inc (NASDAQ: KURA) to $29 from $27. The analysts say that evidence of an effective and tolerable agent and a clear recommended phase 2 dose f...
Kura Oncology to Participate in Three Upcoming Investor Conferences
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment o...
Kura Oncology Reports First Quarter 2022 Financial Results
– Enrollment completed in Phase 1b expansion cohorts for ziftomenib; topline data expected in third quarter, full data presentation in fourth quarter –
Kura Oncology to Report First Quarter 2022 Financial Results
SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer
– Late-breaking presentation at AACR demonstrates potential to significantly delay onset of drug resistance to EGFR-targeted therapies through combination with a farnesyl transferase inhibitor –
Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Meeting
– Presentations to highlight significant opportunities targeting farnesyl transferase inhibition – – Presentations to highlight significant opportunities targeting farnesyl transferase inhibition –
Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results
– Patient enrollment continues in KOMET-001 Phase 1b study of ziftomenib (KO-539) in AML –
Kura Oncology to Report Fourth Quarter and Full Year 2021 Financial Results
SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...